Liver cancer combo trial halted early – what it means
NCT ID NCT04050462
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy drug nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. Only 13 participants were enrolled before the study was terminated. The goal was to see if the combinations improved response rates, but the early stop limits what can be concluded.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab combined with either BMS-986253 or cabiralizumab
What this could lead to
If successful, this could point toward a more effective combination therapy for advanced liver cancer that is not treatable with surgery.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The combinations may not work better than nivolumab alone and could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States